Sánchez-Carbayo M - Search Results

1

Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer.

Sánchez-Carbayo M, Urrutia M, Silva JM, Romaní R, De Buitrago JM, Navajo JA. Sánchez-Carbayo M, et al. J Urol. 2001 May;165(5):1462-7. J Urol. 2001. PMID: 11342897

2

Urinary tissue polypeptide-specific antigen for the diagnosis of bladder cancer.

Sánchez-Carbayo M, Urrutia M, Silva JM, Romaní R, García J, Alférez F, González deBuitrago JM, Navajo JA. Sánchez-Carbayo M, et al. Urology. 2000 Apr;55(4):526-32. doi: 10.1016/s0090-4295(99)00557-9. Urology. 2000. PMID: 10736496

3

[Cytokeratins (UBC and CYFRA 21-1) and nuclear matrix proteins (NMP22) as urine tumor markers in the diagnosis of bladder cancer].

Sánchez-Carbayo M, Urrutia M, Hernández-Cerceño ML, González de Buitrago JM, Navajo JA. Sánchez-Carbayo M, et al. Med Clin (Barc). 2000 Mar 18;114(10):361-6. doi: 10.1016/s0025-7753(00)71298-x. Med Clin (Barc). 2000. PMID: 10786344 Spanish.

4

Evaluation of two new urinary tumor markers: bladder tumor fibronectin and cytokeratin 18 for the diagnosis of bladder cancer.

Sánchez-Carbayo M, Urrutia M, González de Buitrago JM, Navajo JA. Sánchez-Carbayo M, et al. Clin Cancer Res. 2000 Sep;6(9):3585-94. Clin Cancer Res. 2000. PMID: 10999749 Clinical Trial.

5

Serial urinary IL-2, IL-6, IL-8, TNFalpha, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG.

Sanchez-Carbayo M, Urrutia M, Romani R, Herrero M, Gonzalez de Buitrago JM, Navajo JA. Sanchez-Carbayo M, et al. Anticancer Res. 2001 Jul-Aug;21(4B):3041-7. Anticancer Res. 2001. PMID: 11712808 Clinical Trial.

6

Diagnostic performance of the urinary bladder carcinoma antigen ELISA test and multiparametric DNA/cytokeratin flow cytometry in urine voided samples from patients with bladder carcinoma.

Sánchez-Carbayo M, Ciudad J, Urrutia M, Navajo JA, Orfao A. Sánchez-Carbayo M, et al. Cancer. 2001 Dec 1;92(11):2811-9. doi: 10.1002/1097-0142(20011201)92:11<2811::aid-cncr10101>3.0.co;2-t. Cancer. 2001. PMID: 11753954

7

Utility of serial urinary tumor markers to individualize intervals between cystoscopies in the monitoring of patients with bladder carcinoma.

Sánchez-Carbayo M, Urrutia M, González de Buitrago JM, Navajo JA. Sánchez-Carbayo M, et al. Cancer. 2001 Dec 1;92(11):2820-8. doi: 10.1002/1097-0142(20011201)92:11<2820::aid-cncr10092>3.0.co;2-i. Cancer. 2001. PMID: 11753955

8

Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer.

Sánchez-Carbayo M, Herrero E, Megías J, Mira A, Soria F. Sánchez-Carbayo M, et al. J Urol. 1999 Dec;162(6):1951-6. doi: 10.1016/S0022-5347(05)68076-7. J Urol. 1999. PMID: 10569545

9

Initial evaluation of the diagnostic performance of the new urinary bladder cancer antigen test as a tumor marker for transitional cell carcinoma of the bladder.

Sánchez-Carbayo M, Herrero E, Megias J, Mira A, Espasa A, Chinchilla V, Soria F. Sánchez-Carbayo M, et al. J Urol. 1999 Apr;161(4):1110-5. J Urol. 1999. PMID: 10081849 Clinical Trial.

10

Initial evaluation of the new urinary bladder cancer rapid test in the detection of transitional cell carcinoma of the bladder.

Sánchez-Carbayo M, Herrero E, Megías J, Mira A, Soria F. Sánchez-Carbayo M, et al. Urology. 1999 Oct;54(4):656-61. doi: 10.1016/s0090-4295(99)00195-8. Urology. 1999. PMID: 10510924 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

104 results

Search Page

Filters